Biopharmaceutical Lab Equipment Global Market Report 2025

The biopharmaceutical lab equipment market size has grown strongly in recent years. It will grow from $16.44 billion in 2024 to $17.77 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. Growth during the historic period can be attributed to rising biopharmaceutical research and development expenditure, increasing demand for biologics, a growing prevalence of chronic diseases, the global expansion of clinical trials, and rising investments in drug discovery.

The biopharmaceutical lab equipment market size is expected to see strong growth in the next few years. It will grow to $23.93 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Growth during the forecast period is expected to be driven by the rising adoption of personalized medicine, increasing demand for high-throughput screening, a growing emphasis on enhancing biomanufacturing efficiency, the expansion of emerging biopharma companies, and the rising need for advanced analytical tools. Key trends anticipated during the forecast period include technological progress in lab automation, innovations in bioprocessing equipment, advancements in analytical instrumentation, ongoing research and development in biologics manufacturing, and improvements in cell culture technologies.

The growing focus on personalized medicine is expected to drive the expansion of the biopharmaceutical lab equipment market in the coming years. Personalized medicine is a patient-centered approach that customizes treatment and prevention strategies based on individual variations in genes, environments, and lifestyles. The increasing adoption of personalized medicine is fueled by advancements in genomic sequencing technologies and data analytics, allowing healthcare professionals to create more accurate diagnostic tools and targeted therapies for individual patients. This shift toward precision-based healthcare increases the need for advanced laboratory equipment capable of analyzing genetic data, developing targeted therapies, and supporting clinical research for individualized treatments. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and healthcare organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, compared to six in 2022. Therefore, the growing focus on personalized medicine is driving the growth of the biopharmaceutical lab equipment market.

Major companies in the biopharmaceutical lab equipment market are developing innovative solutions such as high-resolution mass analysis systems to improve testing accuracy, streamline workflows, and enhance laboratory efficiency. A high-resolution mass analysis system is an advanced instrument that measures the mass-to-charge ratio of ions with high precision to identify and quantify complex molecules, supporting applications in proteomics, pharmaceuticals, and chemical analysis. For instance, in June 2025, Thermo Fisher Scientific, a US-based life sciences company, introduced next-generation mass spectrometry instruments featuring Thermo Scientific OptiSpray technology. These systems provide exceptional speed and sensitivity for detecting proteins, metabolites, and other biomolecules, supporting advanced precision medicine research. Key features include high-resolution mass analysis, optimized workflows for multiomics studies, user-friendly software for data processing, strong automation for sample handling, and flexible integration with environmental and food safety research. These innovations enable researchers to produce consistent, high-quality data and accelerate discoveries in complex disease research.

In July 2025, Advanced Instruments LLC, a US-based manufacturing company, acquired Nova Biomedical Corporation for an undisclosed amount. The acquisition aims to establish a global life science platform under the Nova Biomedical brand by integrating complementary technologies, expanding global presence, accelerating innovation, and providing greater value to customers in biopharmaceutical and clinical markets. This initiative is expected to enhance patient care and drive long-term sustainable growth. Nova Biomedical Corporation is a US-based technology company that provides biopharmaceutical lab equipment.

Major players in the biopharmaceutical lab equipment market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE HealthCare Technologies Inc., Agilent Technologies Inc., Hitachi High-Tech Corporation, Illumina Inc., Mettler-Toledo International Inc., Shimadzu Corporation, Bruker Corporation, Waters Corporation, Horiba Ltd., Eppendorf SE, Tecan Group Ltd., Hamilton Company, Oxford Instruments plc, Telstar SA, Advanced Instruments LLC, PBS Biotech Inc., Logos Biosystems Inc., Napro Scientific Inc., and Accumax Lab Devices Pvt. Ltd.

North America was the largest region in the biopharmaceutical lab equipment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biopharmaceutical lab equipment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The biopharmaceutical lab equipment market research report is one of a series of new reports that provides biopharmaceutical lab equipment market statistics, including biopharmaceutical lab equipment industry global market size, regional shares, competitors with a biopharmaceutical lab equipment market share, detailed biopharmaceutical lab equipment market segments, market trends and opportunities, and any further data you may need to thrive in the biopharmaceutical lab equipment industry. The biopharmaceutical lab equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Biopharmaceutical lab equipment comprises instruments and devices designed to aid in the development, testing, and analysis of biopharmaceutical products. It enables accurate measurement, control, and manipulation of biological and chemical processes. This equipment improves experimental precision and reproducibility, ensuring dependable results. Its primary role is to support efficient and high-quality research within the field of biopharmaceutical sciences.

The key product types of biopharmaceutical lab equipment include chromatography systems, mass spectrometers, polymerase chain reaction (PCR) equipment, cell culture systems, microscopes, and others. Chromatography systems are utilized to separate, identify, and purify components within complex biological mixtures, ensuring accurate analysis and production in biopharmaceutical laboratories. The technologies involved include single-use technology, continuous processing technology, cell culture technology, filtration technology, and high-throughput screening technology. Laboratories are categorized by size into small-scale, medium-scale, and large-scale labs. This equipment is used in various applications such as drug discovery, clinical diagnostics, research and development, quality control, and others, and serves multiple end-users including pharmaceutical companies, biotechnology companies, academic and research institutions, and others.

The countries covered in the biopharmaceutical lab equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The biopharmaceutical lab equipment market consists of sales of centrifuges, bioreactors, incubators, autoclaves, spectrophotometers, freezers, pipettes, microplate readers, liquid handling robots, analytical balances, and biosafety cabinets. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.